TR200200201T2 - İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler. - Google Patents

İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler.

Info

Publication number
TR200200201T2
TR200200201T2 TR2002/00201T TR200200201T TR200200201T2 TR 200200201 T2 TR200200201 T2 TR 200200201T2 TR 2002/00201 T TR2002/00201 T TR 2002/00201T TR 200200201 T TR200200201 T TR 200200201T TR 200200201 T2 TR200200201 T2 TR 200200201T2
Authority
TR
Turkey
Prior art keywords
oligonucleotides
human
inhibition
expression
oligonucleotide
Prior art date
Application number
TR2002/00201T
Other languages
English (en)
Inventor
Uhlmann Eugen
Greiner Beate
Unger Eberhard
Gothe Gislinde
Schwerdel Marc
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200200201T2 publication Critical patent/TR200200201T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu mevcut bulus, bir insan eg5'inin belirli bir parçasi yada buradan mutasyona ugramis sekilde kodlayici nükleik asit sekansina uyan bir sekans bulundurumasi ile tanimlanan bir oligonükleotit yada bunun derivatlarindan birisi ile ilgilidir; ayrica bulus, oligonükleotit imalatina dair bir metot ve bunun kullanimini kapsar.
TR2002/00201T 1999-07-28 2000-07-21 İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler. TR200200201T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19935303A DE19935303A1 (de) 1999-07-28 1999-07-28 Oligonukleotide zur Inhibierung der Expression von humanem eg5

Publications (1)

Publication Number Publication Date
TR200200201T2 true TR200200201T2 (tr) 2002-05-21

Family

ID=7916259

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00201T TR200200201T2 (tr) 1999-07-28 2000-07-21 İnsan eg5'in ekspresyonunun engellenmesine dair oligonükleotitler.

Country Status (26)

Country Link
US (1) US6472521B1 (tr)
EP (1) EP1204742A2 (tr)
JP (1) JP2003505080A (tr)
KR (1) KR20020033744A (tr)
CN (1) CN1165617C (tr)
AR (1) AR024953A1 (tr)
AU (1) AU6568200A (tr)
BR (1) BR0013180A (tr)
CA (1) CA2380192A1 (tr)
CZ (1) CZ2002324A3 (tr)
DE (1) DE19935303A1 (tr)
EE (1) EE200200044A (tr)
HK (1) HK1048337B (tr)
HR (1) HRP20020075A2 (tr)
HU (1) HUP0202794A3 (tr)
IL (1) IL147541A0 (tr)
MX (1) MXPA02000817A (tr)
NO (1) NO20020365L (tr)
NZ (1) NZ516839A (tr)
PL (1) PL353733A1 (tr)
RU (1) RU2249458C2 (tr)
SK (1) SK1162002A3 (tr)
TR (1) TR200200201T2 (tr)
WO (1) WO2001007602A2 (tr)
YU (1) YU91901A (tr)
ZA (1) ZA200200655B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6440686B1 (en) 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) * 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
JP2006521794A (ja) * 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647728C (en) * 2006-03-31 2014-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
WO2007140000A2 (en) * 2006-05-26 2007-12-06 Regado Biosciences, Inc. Administration of the reg1 anticoagulation system
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
JP5753382B2 (ja) * 2007-11-06 2015-07-22 アディウティーダ ファーマシューティカルズ ゲーエムベーハー 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
PH12018501678B1 (en) 2011-08-30 2022-08-10 Astex Pharmaceuticals Inc Decitabine derivative formulations
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
KR102365486B1 (ko) * 2013-08-28 2022-02-18 아이오니스 파마수티컬즈, 인코포레이티드 프리칼리크레인 (pkk) 발현의 조절
SG10201808903UA (en) * 2013-10-11 2018-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US10280423B2 (en) * 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
EP3316685A4 (en) 2015-07-02 2019-03-13 Otsuka Pharmaceutical Co., Ltd. Lyophilized Pharmaceutical Compositions
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171066A3 (de) 1984-08-09 1989-02-01 Siemens Aktiengesellschaft Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
ES2099718T3 (es) 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
US6033909A (en) 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
IL104461A (en) 1992-01-22 2001-05-20 Hoechst Ag Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
ES2103408T3 (es) 1992-09-24 1997-09-16 Hoechst Ag Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente.
GB9311113D0 (en) * 1993-05-28 1993-07-14 Medical Res Council Probes
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DE59607750D1 (de) 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US6309821B1 (en) * 1996-05-16 2001-10-30 Incyte Genomics, Inc. DNA encoding a PAC10 human homolog
EP1066382A1 (en) * 1997-07-23 2001-01-10 Brigham & Women's Hospital, Inc. Lens epithelial cell derived growth factor
EP1053319A2 (en) * 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii

Also Published As

Publication number Publication date
CN1367828A (zh) 2002-09-04
JP2003505080A (ja) 2003-02-12
HUP0202794A3 (en) 2006-03-28
WO2001007602A2 (de) 2001-02-01
HK1048337B (zh) 2005-02-25
IL147541A0 (en) 2002-08-14
YU91901A (sh) 2003-02-28
AU6568200A (en) 2001-02-13
HK1048337A1 (en) 2003-03-28
NO20020365D0 (no) 2002-01-23
NZ516839A (en) 2004-04-30
BR0013180A (pt) 2002-04-09
HUP0202794A2 (en) 2003-03-28
DE19935303A1 (de) 2001-02-08
KR20020033744A (ko) 2002-05-07
AR024953A1 (es) 2002-10-30
RU2249458C2 (ru) 2005-04-10
PL353733A1 (en) 2003-12-01
CZ2002324A3 (cs) 2002-05-15
EP1204742A2 (de) 2002-05-15
CA2380192A1 (en) 2001-02-01
MXPA02000817A (es) 2002-07-30
ZA200200655B (en) 2003-09-23
WO2001007602A3 (de) 2001-05-17
HRP20020075A2 (en) 2005-10-31
CN1165617C (zh) 2004-09-08
SK1162002A3 (en) 2002-06-04
US6472521B1 (en) 2002-10-29
NO20020365L (no) 2002-03-25
EE200200044A (et) 2003-06-16

Similar Documents

Publication Publication Date Title
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
ATE300613T1 (de) Menschliche, für zyklische nukleotide spezifische phosphodiesterase
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
BR9811854B1 (pt) processo de preparação de 3,3-dimetilbutiraldeìdo por oxidação de 3,3-dimetilbutanol.
ATE190357T1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
CU23082A3 (es) 4-carboxiamino-2-subsituidos-1,2,3,4- tetrahidroquinolas como inhibidores cetp
BR0013180A (pt) Oligonucleotìdeos para inibição da expressão de eg5 humano
NO983716D0 (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
IT1295970B1 (it) Metodo di sequenziazione di oggetti postali.
BR0210544A (pt) Formação de multiplex de ácido nucleico
DE69939114D1 (de) Nukleinsäuresequenzfamilie und entsprechende proteinsequenzen, die humane endogene retrovirale motive enthalten, und ihre anwendungen
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69739346D1 (de) Gereinigtes sr-p70 protein
DK1108786T3 (da) Hidtil ukendt kollektin
NO307705B1 (no) Substituerte N-etyl-glycinderivater for fremstilling av PNA og PNA-/DNA-hybrider, samt anvendelse av samme for fremstilling av PNA og PNA-/DNA-hybrider
ATE495268T1 (de) Nukleinsäureamplifizierung und detektion von mykobacterium-spezies
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
DE69434809D1 (de) Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen
ATE335824T1 (de) Isolierte luziferasen sowie deren verwendung
ATE364616T1 (de) Nucleinsäuremolekül, kit und verwendung